Drugs. 2001;61(2):253-60; discussion 261. doi: 10.2165/00003495-200161020-00008.


* Omalizumab is a recombinant humanised monoclonal antibody which specifically binds to the C epsilon3 domain of immunoglobulin (Ig) E, the site of high-affinity IgE receptor binding. * Improvements in asthma symptoms and health-related quality-of-life, and a significant reduction in the frequency of asthma exacerbations were seen in allergic asthmatic patients treated with omalizumab. * Omalizumab was also effective in the treatment of children with allergic asthma demonstrating improvements in health-related quality-of-life and significant dosage reductions of inhaled corticosteroids. * Administration of omalizumab to patients with allergic rhinitis resulted in a rapid dose-dependent suppression of serum free IgE levels. * Omalizumab significantly improved health-related quality-of-life and nasal symptoms in patients with seasonal allergic rhinitis. Antihistamine requirements were also significantly reduced following treatment. * Adverse events were infrequent in clinical trials of omalizumab, and not significantly different from placebo. The most frequent drug-related event was mild to moderate urticaria.

MeSH terms

  • Anti-Allergic Agents / pharmacology*
  • Anti-Allergic Agents / therapeutic use
  • Anti-Asthmatic Agents / pharmacology*
  • Anti-Asthmatic Agents / therapeutic use
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Asthma / drug therapy
  • Asthma / immunology
  • Asthma / pathology
  • Histamine Antagonists / therapeutic use
  • Histamine Release / drug effects
  • Humans
  • Immunoglobulin E / blood
  • Immunoglobulin E / immunology
  • Omalizumab
  • Rhinitis, Allergic, Seasonal / immunology


  • Anti-Allergic Agents
  • Anti-Asthmatic Agents
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Histamine Antagonists
  • Omalizumab
  • Immunoglobulin E